News & Updates

The addition of a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor to fulvestrant provides a consistent benefit in overall survival (OS) in patients with hormone receptor (HR)–positive, HER2-negative, advanced or metastatic breast cancer in first-, second- and later-line settings and in most clinicopathological subgroups of interest, results of a US FDA pooled analysis of have shown.

A recent study has provided a detailed proteomic profile that identified proteins associated with the pathogenesis and disease progression of chronic obstructive pulmonary disease (COPD), which can then help in the creation of platform to develop effective new treatment strategies.

Some skin diseases present with seasonal patterns, including warts, eczema, and atopic dermatitis, a new study has found. Though more common in winter, acne remains the most prevalent diagnosis in dermatology clinics.